Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study
In September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone infected with HIV irrespective of their CD4 cell count. Studies of universal treatment and expanded prevention of HIV differ widely in their projections of effects and the associated costs, so we did...
Saved in:
| Published in: | The Lancet. Public health Vol. 2; no. 5; pp. e223 - e230 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Elsevier Ltd
01.05.2017
Elsevier |
| Subjects: | |
| ISSN: | 2468-2667, 2468-2667 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | In September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone infected with HIV irrespective of their CD4 cell count. Studies of universal treatment and expanded prevention of HIV differ widely in their projections of effects and the associated costs, so we did this analysis to attempt to find a consensus.
We used data on HIV from the Joint UN Programme on HIV and AIDS (UNAIDS) from 1988 to 2013 and from data from WHO on tuberculosis from 1980 to to 2013 to fit a dynamical model to time trends in HIV prevalence, antiretroviral therapy (ART) coverage, and tuberculosis notification rates in South Africa. We then used the model to estimate current trends and project future patterns in HIV prevalence and incidence, AIDS-related mortality, and tuberculosis notification rates, and we used data from the South African National AIDS Council to assess current and future costs under different combinations of treatment and prevention approaches. We considered two treatment strategies: the Constant Effort strategy, in which people infected with HIV continue to start treatment at the rate in 2016, and the Expanded Treatment and Prevention (ETP) strategy, in which testing rates are increased, treatment is started immediately after HIV is detected, and prevention programmes are expanded.
Our estimates show that HIV incidence among adults aged 15 years or older fell from 2·3% per year in 1996 to 0·65% per year in 2016, AIDS-related mortality decreased from 1·4% per year in 2006 to 0·37% per year in 2016, and both continue to fall at a relative rate of 17% per year. Our model shows that maintenance of Constant Effort will have a substantial effect on HIV but will not end AIDS, whereas ETP could end AIDS by 2030, with incidence of HIV and AIDs-related mortality rates both at less than one event per 1000 adults per year. Under ETP the annual cost of health care and prevention will increase from US$2·3 billion in 2016 to $2·9 billion in 2018, then decrease to $1·7 billion in 2030 and $0·9 billion in 2050. Over the next 35 years, the expansion of treatment will avert an additional 3·8 million new infections, save 1·1 million lives, and save $3·2 billion compared with continuing Constant Effort up to 2050. Expansion of prevention, including provision of pre-exposure prophylaxis, condom distribution, and male circumcision, could avert a further 150 000 new infections, save 5000 lives, and cost an additional $5·7 billion compared with Constant Effort.
Our results suggest that South Africa is on track to reduce HIV incidence and AIDS-related mortality substantially by 2030, saving both lives and money. Success will depend on high rates of HIV testing, ART delivery and adherence, good patient monitoring and support, and data to monitor progress.
None. |
|---|---|
| AbstractList | In September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone infected with HIV irrespective of their CD4 cell count. Studies of universal treatment and expanded prevention of HIV differ widely in their projections of effects and the associated costs, so we did this analysis to attempt to find a consensus.
We used data on HIV from the Joint UN Programme on HIV and AIDS (UNAIDS) from 1988 to 2013 and from data from WHO on tuberculosis from 1980 to to 2013 to fit a dynamical model to time trends in HIV prevalence, antiretroviral therapy (ART) coverage, and tuberculosis notification rates in South Africa. We then used the model to estimate current trends and project future patterns in HIV prevalence and incidence, AIDS-related mortality, and tuberculosis notification rates, and we used data from the South African National AIDS Council to assess current and future costs under different combinations of treatment and prevention approaches. We considered two treatment strategies: the Constant Effort strategy, in which people infected with HIV continue to start treatment at the rate in 2016, and the Expanded Treatment and Prevention (ETP) strategy, in which testing rates are increased, treatment is started immediately after HIV is detected, and prevention programmes are expanded.
Our estimates show that HIV incidence among adults aged 15 years or older fell from 2·3% per year in 1996 to 0·65% per year in 2016, AIDS-related mortality decreased from 1·4% per year in 2006 to 0·37% per year in 2016, and both continue to fall at a relative rate of 17% per year. Our model shows that maintenance of Constant Effort will have a substantial effect on HIV but will not end AIDS, whereas ETP could end AIDS by 2030, with incidence of HIV and AIDs-related mortality rates both at less than one event per 1000 adults per year. Under ETP the annual cost of health care and prevention will increase from US$2·3 billion in 2016 to $2·9 billion in 2018, then decrease to $1·7 billion in 2030 and $0·9 billion in 2050. Over the next 35 years, the expansion of treatment will avert an additional 3·8 million new infections, save 1·1 million lives, and save $3·2 billion compared with continuing Constant Effort up to 2050. Expansion of prevention, including provision of pre-exposure prophylaxis, condom distribution, and male circumcision, could avert a further 150 000 new infections, save 5000 lives, and cost an additional $5·7 billion compared with Constant Effort.
Our results suggest that South Africa is on track to reduce HIV incidence and AIDS-related mortality substantially by 2030, saving both lives and money. Success will depend on high rates of HIV testing, ART delivery and adherence, good patient monitoring and support, and data to monitor progress.
None. SummaryBackgroundIn September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone infected with HIV irrespective of their CD4 cell count. Studies of universal treatment and expanded prevention of HIV differ widely in their projections of effects and the associated costs, so we did this analysis to attempt to find a consensus. MethodsWe used data on HIV from the Joint UN Programme on HIV and AIDS (UNAIDS) from 1988 to 2013 and from data from WHO on tuberculosis from 1980 to to 2013 to fit a dynamical model to time trends in HIV prevalence, antiretroviral therapy (ART) coverage, and tuberculosis notification rates in South Africa. We then used the model to estimate current trends and project future patterns in HIV prevalence and incidence, AIDS-related mortality, and tuberculosis notification rates, and we used data from the South African National AIDS Council to assess current and future costs under different combinations of treatment and prevention approaches. We considered two treatment strategies: the Constant Effort strategy, in which people infected with HIV continue to start treatment at the rate in 2016, and the Expanded Treatment and Prevention (ETP) strategy, in which testing rates are increased, treatment is started immediately after HIV is detected, and prevention programmes are expanded. FindingsOur estimates show that HIV incidence among adults aged 15 years or older fell from 2·3% per year in 1996 to 0·65% per year in 2016, AIDS-related mortality decreased from 1·4% per year in 2006 to 0·37% per year in 2016, and both continue to fall at a relative rate of 17% per year. Our model shows that maintenance of Constant Effort will have a substantial effect on HIV but will not end AIDS, whereas ETP could end AIDS by 2030, with incidence of HIV and AIDs-related mortality rates both at less than one event per 1000 adults per year. Under ETP the annual cost of health care and prevention will increase from US$2·3 billion in 2016 to $2·9 billion in 2018, then decrease to $1·7 billion in 2030 and $0·9 billion in 2050. Over the next 35 years, the expansion of treatment will avert an additional 3·8 million new infections, save 1·1 million lives, and save $3·2 billion compared with continuing Constant Effort up to 2050. Expansion of prevention, including provision of pre-exposure prophylaxis, condom distribution, and male circumcision, could avert a further 150 000 new infections, save 5000 lives, and cost an additional $5·7 billion compared with Constant Effort. InterpretationOur results suggest that South Africa is on track to reduce HIV incidence and AIDS-related mortality substantially by 2030, saving both lives and money. Success will depend on high rates of HIV testing, ART delivery and adherence, good patient monitoring and support, and data to monitor progress. FundingNone. In September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone infected with HIV irrespective of their CD4 cell count. Studies of universal treatment and expanded prevention of HIV differ widely in their projections of effects and the associated costs, so we did this analysis to attempt to find a consensus.BACKGROUNDIn September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone infected with HIV irrespective of their CD4 cell count. Studies of universal treatment and expanded prevention of HIV differ widely in their projections of effects and the associated costs, so we did this analysis to attempt to find a consensus.We used data on HIV from the Joint UN Programme on HIV and AIDS (UNAIDS) from 1988 to 2013 and from data from WHO on tuberculosis from 1980 to to 2013 to fit a dynamical model to time trends in HIV prevalence, antiretroviral therapy (ART) coverage, and tuberculosis notification rates in South Africa. We then used the model to estimate current trends and project future patterns in HIV prevalence and incidence, AIDS-related mortality, and tuberculosis notification rates, and we used data from the South African National AIDS Council to assess current and future costs under different combinations of treatment and prevention approaches. We considered two treatment strategies: the Constant Effort strategy, in which people infected with HIV continue to start treatment at the rate in 2016, and the Expanded Treatment and Prevention (ETP) strategy, in which testing rates are increased, treatment is started immediately after HIV is detected, and prevention programmes are expanded.METHODSWe used data on HIV from the Joint UN Programme on HIV and AIDS (UNAIDS) from 1988 to 2013 and from data from WHO on tuberculosis from 1980 to to 2013 to fit a dynamical model to time trends in HIV prevalence, antiretroviral therapy (ART) coverage, and tuberculosis notification rates in South Africa. We then used the model to estimate current trends and project future patterns in HIV prevalence and incidence, AIDS-related mortality, and tuberculosis notification rates, and we used data from the South African National AIDS Council to assess current and future costs under different combinations of treatment and prevention approaches. We considered two treatment strategies: the Constant Effort strategy, in which people infected with HIV continue to start treatment at the rate in 2016, and the Expanded Treatment and Prevention (ETP) strategy, in which testing rates are increased, treatment is started immediately after HIV is detected, and prevention programmes are expanded.Our estimates show that HIV incidence among adults aged 15 years or older fell from 2·3% per year in 1996 to 0·65% per year in 2016, AIDS-related mortality decreased from 1·4% per year in 2006 to 0·37% per year in 2016, and both continue to fall at a relative rate of 17% per year. Our model shows that maintenance of Constant Effort will have a substantial effect on HIV but will not end AIDS, whereas ETP could end AIDS by 2030, with incidence of HIV and AIDs-related mortality rates both at less than one event per 1000 adults per year. Under ETP the annual cost of health care and prevention will increase from US$2·3 billion in 2016 to $2·9 billion in 2018, then decrease to $1·7 billion in 2030 and $0·9 billion in 2050. Over the next 35 years, the expansion of treatment will avert an additional 3·8 million new infections, save 1·1 million lives, and save $3·2 billion compared with continuing Constant Effort up to 2050. Expansion of prevention, including provision of pre-exposure prophylaxis, condom distribution, and male circumcision, could avert a further 150 000 new infections, save 5000 lives, and cost an additional $5·7 billion compared with Constant Effort.FINDINGSOur estimates show that HIV incidence among adults aged 15 years or older fell from 2·3% per year in 1996 to 0·65% per year in 2016, AIDS-related mortality decreased from 1·4% per year in 2006 to 0·37% per year in 2016, and both continue to fall at a relative rate of 17% per year. Our model shows that maintenance of Constant Effort will have a substantial effect on HIV but will not end AIDS, whereas ETP could end AIDS by 2030, with incidence of HIV and AIDs-related mortality rates both at less than one event per 1000 adults per year. Under ETP the annual cost of health care and prevention will increase from US$2·3 billion in 2016 to $2·9 billion in 2018, then decrease to $1·7 billion in 2030 and $0·9 billion in 2050. Over the next 35 years, the expansion of treatment will avert an additional 3·8 million new infections, save 1·1 million lives, and save $3·2 billion compared with continuing Constant Effort up to 2050. Expansion of prevention, including provision of pre-exposure prophylaxis, condom distribution, and male circumcision, could avert a further 150 000 new infections, save 5000 lives, and cost an additional $5·7 billion compared with Constant Effort.Our results suggest that South Africa is on track to reduce HIV incidence and AIDS-related mortality substantially by 2030, saving both lives and money. Success will depend on high rates of HIV testing, ART delivery and adherence, good patient monitoring and support, and data to monitor progress.INTERPRETATIONOur results suggest that South Africa is on track to reduce HIV incidence and AIDS-related mortality substantially by 2030, saving both lives and money. Success will depend on high rates of HIV testing, ART delivery and adherence, good patient monitoring and support, and data to monitor progress.None.FUNDINGNone. Background: In September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone infected with HIV irrespective of their CD4 cell count. Studies of universal treatment and expanded prevention of HIV differ widely in their projections of effects and the associated costs, so we did this analysis to attempt to find a consensus. Methods: We used data on HIV from the Joint UN Programme on HIV and AIDS (UNAIDS) from 1988 to 2013 and from data from WHO on tuberculosis from 1980 to to 2013 to fit a dynamical model to time trends in HIV prevalence, antiretroviral therapy (ART) coverage, and tuberculosis notification rates in South Africa. We then used the model to estimate current trends and project future patterns in HIV prevalence and incidence, AIDS-related mortality, and tuberculosis notification rates, and we used data from the South African National AIDS Council to assess current and future costs under different combinations of treatment and prevention approaches. We considered two treatment strategies: the Constant Effort strategy, in which people infected with HIV continue to start treatment at the rate in 2016, and the Expanded Treatment and Prevention (ETP) strategy, in which testing rates are increased, treatment is started immediately after HIV is detected, and prevention programmes are expanded. Findings: Our estimates show that HIV incidence among adults aged 15 years or older fell from 2·3% per year in 1996 to 0·65% per year in 2016, AIDS-related mortality decreased from 1·4% per year in 2006 to 0·37% per year in 2016, and both continue to fall at a relative rate of 17% per year. Our model shows that maintenance of Constant Effort will have a substantial effect on HIV but will not end AIDS, whereas ETP could end AIDS by 2030, with incidence of HIV and AIDs-related mortality rates both at less than one event per 1000 adults per year. Under ETP the annual cost of health care and prevention will increase from US$2·3 billion in 2016 to $2·9 billion in 2018, then decrease to $1·7 billion in 2030 and $0·9 billion in 2050. Over the next 35 years, the expansion of treatment will avert an additional 3·8 million new infections, save 1·1 million lives, and save $3·2 billion compared with continuing Constant Effort up to 2050. Expansion of prevention, including provision of pre-exposure prophylaxis, condom distribution, and male circumcision, could avert a further 150 000 new infections, save 5000 lives, and cost an additional $5·7 billion compared with Constant Effort. Interpretation: Our results suggest that South Africa is on track to reduce HIV incidence and AIDS-related mortality substantially by 2030, saving both lives and money. Success will depend on high rates of HIV testing, ART delivery and adherence, good patient monitoring and support, and data to monitor progress. Funding: None. |
| Author | Wollmers, Matthew Granich, Reuben Williams, Brian G Gupta, Somya |
| Author_xml | – sequence: 1 givenname: Brian G surname: Williams fullname: Williams, Brian G email: briangerardwilliams@gmail.com organization: South African Centre for Epidemiological Modelling and Analysis, University of Stellenbosch, Stellenbosch, South Africa – sequence: 2 givenname: Somya surname: Gupta fullname: Gupta, Somya organization: International Association of Providers of AIDS Care, Washington, DC, USA – sequence: 3 givenname: Matthew surname: Wollmers fullname: Wollmers, Matthew organization: Office of the US Global AIDS Coordinator, Washington, DC, USA – sequence: 4 givenname: Reuben surname: Granich fullname: Granich, Reuben organization: International Association of Providers of AIDS Care, Washington, DC, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29253488$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkV1rFDEUhoNUbF37E5Rc1ovVZCYzySgqpahdKChUpXfhTD622c5O1iRT2H_fzE5dpCD1Kh-858nM-zxHB73vDUIvKXlDCa3fXhasFvOirvkJ5a9LQup6fvUEHe2vD_7aH6LjGFeEECrysSqeocOiKaqSCXGEbr4HvwwmRgy9xpvg48aoFLH1Aadrg5XvU_Ad9hafL37tQmloTVBD56OL2PX40g_pGp_a4BS8w4D1tod13nd47bXpOtcvcUyD3r5ATy100RzfrzP088vnH2fn84tvXxdnpxdzVQme5soyq5q25qA1gNKkqbmGiitGLGetBgJcgGBGWFoIoy3nDZSqFC1TRc6WM7SYuNrDSm6CW0PYSg9O7i58WEoIyanOSAUNgCDMFqRhXLCW1UVlWpvRdclbklknEytX83swMcm1iyr_FfTGD1HShgtOK5L7nKFX99GhXRu9f_hP2TlQTQGVa47B2H2EEjl6lTuvcpQmKZc7r_Iqz71_MKdcguRGNeC6R6c_TdMmV37rTJBROdMro13IqnMn7lHCxwcElaWOhm_M1sSVH0KffUoqYyHJBBkZlO8II-DDvwH_8QF3LzXlUQ |
| CitedBy_id | crossref_primary_10_1002_jia2_25191 crossref_primary_10_1007_s40121_018_0210_5 crossref_primary_10_1097_COH_0000000000000580 crossref_primary_10_1371_journal_pone_0215591 crossref_primary_10_1016_S2468_2667_17_30070_1 crossref_primary_10_1371_journal_pone_0251303 crossref_primary_10_1186_s12992_019_0466_x crossref_primary_10_4102_sajhivmed_v19i1_796 crossref_primary_10_1007_s10461_023_04023_1 crossref_primary_10_1186_s12913_019_4423_4 crossref_primary_10_1016_S0140_6736_17_31832_9 crossref_primary_10_1097_QAI_0000000000001956 crossref_primary_10_1371_journal_pone_0202473 crossref_primary_10_1016_j_contraception_2022_07_005 crossref_primary_10_1371_journal_pone_0264811 crossref_primary_10_1155_2019_6951389 crossref_primary_10_1371_journal_pone_0226422 crossref_primary_10_1080_15381501_2024_2388162 crossref_primary_10_1097_QAI_0000000000001852 crossref_primary_10_1186_s12879_018_3383_3 |
| Cites_doi | 10.1016/S2352-3018(16)00037-0 10.1155/2011/567408 10.3402/gha.v9.30314 10.1097/QAD.0000000000001155 10.1007/s11904-015-0264-x 10.1016/S1473-3099(13)70363-3 10.1136/sti.2005.017442 10.1007/s40273-015-0279-6 10.1097/QCO.0b013e328011ab73 10.1371/journal.pone.0142908 10.2471/BLT.08.051474 10.1016/S0140-6736(00)02061-4 10.1073/pnas.1005660107 10.7326/M16-0799 10.1371/journal.pmed.1000178 10.1371/journal.pmed.1001509 10.1086/595566 10.1097/QAD.0b013e32833016ce 10.1086/511878 10.2471/BLT.09.066126 10.1097/QAI.0b013e3181b327e7 |
| ContentType | Journal Article |
| Copyright | 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license. Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license – notice: The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license – notice: Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license. Published by Elsevier Ltd.. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
| DOI | 10.1016/S2468-2667(17)30066-X |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 2468-2667 |
| EndPage | e230 |
| ExternalDocumentID | oai_doaj_org_article_ca9aa804f2094784b4625ebf8f1637b0 29253488 10_1016_S2468_2667_17_30066_X S246826671730066X 1_s2_0_S246826671730066X |
| Genre | Journal Article |
| GrantInformation | None. |
| GroupedDBID | .1- .FO 0R~ 53G AAEDW AALRI AAMRU AAXUO ACGFS ACVFH ADBBV ADCNI AEUPX AFPUW AFRHN AFTJW AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS APXCP BCNDV EBS EJD FDB GROUPED_DOAJ M41 M~E O9- OK1 ROL SSZ Z5R ZCN 0SF NCXOZ RIG 6I. AAFTH AFCTW AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c587t-cf4fc9b67addaacd0967da57c40f74bda0a78a84e8f128edf779a3c38b4c29673 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000425586300010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2468-2667 |
| IngestDate | Fri Oct 03 12:47:41 EDT 2025 Sun Nov 09 12:38:37 EST 2025 Thu Apr 03 07:06:46 EDT 2025 Tue Nov 18 22:25:54 EST 2025 Sat Nov 29 06:01:15 EST 2025 Thu Jul 20 20:04:39 EDT 2023 Sun Feb 23 10:19:25 EST 2025 Tue Aug 26 16:31:48 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c587t-cf4fc9b67addaacd0967da57c40f74bda0a78a84e8f128edf779a3c38b4c29673 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/ca9aa804f2094784b4625ebf8f1637b0 |
| PMID | 29253488 |
| PQID | 1978715025 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ca9aa804f2094784b4625ebf8f1637b0 proquest_miscellaneous_1978715025 pubmed_primary_29253488 crossref_primary_10_1016_S2468_2667_17_30066_X crossref_citationtrail_10_1016_S2468_2667_17_30066_X elsevier_sciencedirect_doi_10_1016_S2468_2667_17_30066_X elsevier_clinicalkeyesjournals_1_s2_0_S246826671730066X elsevier_clinicalkey_doi_10_1016_S2468_2667_17_30066_X |
| PublicationCentury | 2000 |
| PublicationDate | 2017-05-01 |
| PublicationDateYYYYMMDD | 2017-05-01 |
| PublicationDate_xml | – month: 05 year: 2017 text: 2017-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | The Lancet. Public health |
| PublicationTitleAlternate | Lancet Public Health |
| PublicationYear | 2017 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Auvert, Lissouba, Cutler, Zarca, Puren, Taljaard (bib24) 2010; 53 Korenromp, Gobet, Fazito, Lara, Bollinger, Stover (bib26) 2016; 10 (bib11) 2000; 355 (bib13) 2016 Weiss, Thomas, Munabi, Hayes (bib22) 2006; 82 Weiss (bib21) 2007; 20 Auvert, Taljaard, Rech (bib20) 2013; 10 Jean, Puren, Cutler (bib15) 2016; 30 Lowenthal, Bakeera-Kitaka, Marukutira, Chapman, Goldrath, Ferrand (bib10) 2014; 14 Ferrand, Lowe, Whande (bib8) 2010; 88 Ferrand, Corbett, Wood (bib7) 2009; 23 (bib2) 2016 (bib5) 2015 Walensky, Borre, Bekker (bib3) 2016; 165 Laurence, Griffiths, Vassall (bib14) 2015; 33 Mansoer, Scheele, Floyd, Dye, Sitienei, Williams (bib12) 2009; 87 Tarnaud, Lissouba, Cutler, Puren, Taljaard, Auvert (bib23) 2011; 2011 Johnson, Chiu, Myer (bib27) 2016; 9 Ferrand, Bandason, Musvaire (bib9) 2010; 7 Gaolathe, Wirth, Holme (bib16) 2016; 3 Williams, Granich, De Cock, Glaziou, Sharma, Dye (bib18) 2010; 107 Williams, Gouws, Somse (bib4) 2015; 12 Williams (bib17) Jul 23, 2013 Black, Kriel, Mitchley, Williams (bib28) Dec 15, 2015 (bib1) 2016 (bib19) 2013 Auvert, Sobngwi-Tambekou, Cutler (bib25) 2009; 199 Ferrand, Luethy, Bwakura, Mujuru, Miller, Corbett (bib6) 2007; 44 Weiss (10.1016/S2468-2667(17)30066-X_bib21) 2007; 20 Ferrand (10.1016/S2468-2667(17)30066-X_bib6) 2007; 44 Korenromp (10.1016/S2468-2667(17)30066-X_bib26) 2016; 10 Walensky (10.1016/S2468-2667(17)30066-X_bib3) 2016; 165 Ferrand (10.1016/S2468-2667(17)30066-X_bib8) 2010; 88 Johnson (10.1016/S2468-2667(17)30066-X_bib27) 2016; 9 Mansoer (10.1016/S2468-2667(17)30066-X_bib12) 2009; 87 Williams (10.1016/S2468-2667(17)30066-X_bib18) 2010; 107 Ferrand (10.1016/S2468-2667(17)30066-X_bib7) 2009; 23 Laurence (10.1016/S2468-2667(17)30066-X_bib14) 2015; 33 (10.1016/S2468-2667(17)30066-X_bib5) 2015 Auvert (10.1016/S2468-2667(17)30066-X_bib25) 2009; 199 (10.1016/S2468-2667(17)30066-X_bib13) 2016 Weiss (10.1016/S2468-2667(17)30066-X_bib22) 2006; 82 Williams (10.1016/S2468-2667(17)30066-X_bib4) 2015; 12 Jean (10.1016/S2468-2667(17)30066-X_bib15) 2016; 30 Ferrand (10.1016/S2468-2667(17)30066-X_bib9) 2010; 7 Auvert (10.1016/S2468-2667(17)30066-X_bib20) 2013; 10 Gaolathe (10.1016/S2468-2667(17)30066-X_bib16) 2016; 3 (10.1016/S2468-2667(17)30066-X_bib1) 2016 Tarnaud (10.1016/S2468-2667(17)30066-X_bib23) 2011; 2011 Black (10.1016/S2468-2667(17)30066-X_bib28) Lowenthal (10.1016/S2468-2667(17)30066-X_bib10) 2014; 14 Williams (10.1016/S2468-2667(17)30066-X_bib17) (10.1016/S2468-2667(17)30066-X_bib11) 2000; 355 Auvert (10.1016/S2468-2667(17)30066-X_bib24) 2010; 53 (10.1016/S2468-2667(17)30066-X_bib19) 2013 29253481 - Lancet Public Health. 2017 May;2(5):e205-e206 |
| References_xml | – volume: 165 start-page: 325 year: 2016 end-page: 333 ident: bib3 article-title: The anticipated clinical and economic effects of 90–90–90 in South Africa publication-title: Ann Intern Med – volume: 53 start-page: 111 year: 2010 end-page: 116 ident: bib24 article-title: Association of oncogenic and nononcogenic human papillomavirus with HIV incidence publication-title: J Acquir Immune Defic Syndr – volume: 30 start-page: 2107 year: 2016 end-page: 2116 ident: bib15 article-title: Level of viral suppression and the cascade of HIV care in a South African semi-urban setting in 2012 publication-title: AIDS – year: Jul 23, 2013 ident: bib17 article-title: Combination prevention for the elimination of HIV. – volume: 23 start-page: 2039 year: 2009 end-page: 2046 ident: bib7 article-title: AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic publication-title: AIDS – volume: 7 start-page: e1000178 year: 2010 ident: bib9 article-title: Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey publication-title: PLoS Med – volume: 10 start-page: e0142908 year: 2016 ident: bib26 article-title: Impact and cost of the HIV/AIDS national strategic plan for Mozambique, 2015–2019—projections with the Spectrum/Goals model publication-title: PLoS One – volume: 88 start-page: 428 year: 2010 end-page: 434 ident: bib8 article-title: Survey of children accessing HIV services in a high prevalence setting: time for adolescents to count? publication-title: Bull World Health Organ – year: 2013 ident: bib19 publication-title: The 2012 National Antenatal Sentinel HIV and Herpes Simplex type-2 prevalence Survey, South Africa – volume: 14 start-page: 627 year: 2014 end-page: 639 ident: bib10 article-title: Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges publication-title: Lancet Infect Dis – volume: 87 start-page: 186 year: 2009 end-page: 192 ident: bib12 article-title: New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya publication-title: Bull World Health Organ – year: 2016 ident: bib2 article-title: AIDSinfo online database – year: 2016 ident: bib1 publication-title: Global AIDS Update 2016 – volume: 12 start-page: 196 year: 2015 end-page: 206 ident: bib4 article-title: Epidemiological trends for HIV in southern Africa: implications for reaching the elimination targets publication-title: Curr HIV/AIDS Rep – volume: 44 start-page: 874 year: 2007 end-page: 878 ident: bib6 article-title: HIV infection presenting in older children and adolescents: a case series from Harare, Zimbabwe publication-title: Clin Infect Dis – volume: 33 start-page: 939 year: 2015 end-page: 955 ident: bib14 article-title: Costs to health services and the patient of treating tuberculosis: a systematic literature review publication-title: Pharmacoeconomics – volume: 107 start-page: 19485 year: 2010 end-page: 19489 ident: bib18 article-title: Antiretroviral therapy for tuberculosis control in nine African countries publication-title: Proc Natl Acad Sci USA – volume: 10 start-page: e1001509 year: 2013 ident: bib20 article-title: Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys publication-title: PLoS Med – volume: 199 start-page: 14 year: 2009 end-page: 19 ident: bib25 article-title: Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in orange farm, South Africa publication-title: J Infect Dis – volume: 82 start-page: 101 year: 2006 end-page: 109 ident: bib22 article-title: Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis publication-title: Sex Transm Infec – volume: 20 start-page: 66 year: 2007 end-page: 72 ident: bib21 article-title: Male circumcision as a preventive measure against HIV and other sexually transmitted diseases publication-title: Curr Opin Infect Dis – volume: 3 start-page: e221 year: 2016 end-page: e230 ident: bib16 article-title: Botswana's progress toward achieving the 2020 UNAIDS 90–90–90 antiretroviral therapy and virological suppression goals: a population-based survey publication-title: Lancet HIV – year: 2016 ident: bib13 publication-title: South African HIV and TB investment case: reference report, phase 1 – volume: 9 start-page: 30314 year: 2016 ident: bib27 article-title: Prospects for HIV control in South Africa: a model-based analysis publication-title: Glob Health Action – year: 2015 ident: bib5 publication-title: Global tuberculosis report – volume: 2011 start-page: 567408 year: 2011 ident: bib23 article-title: Association of low-risk human papillomavirus infection with male circumcision in young men: results from a longitudinal study conducted in Orange Farm (South Africa) publication-title: Infect Dis Obstet Gyneco – year: Dec 15, 2015 ident: bib28 article-title: The burden of HIV in a public hospital in Johannesburg, South Africa – volume: 355 start-page: 1131 year: 2000 end-page: 1137 ident: bib11 article-title: Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active anti-retroviral therapy: a collaborative re-analysis publication-title: Lancet – volume: 3 start-page: e221 year: 2016 ident: 10.1016/S2468-2667(17)30066-X_bib16 article-title: Botswana's progress toward achieving the 2020 UNAIDS 90–90–90 antiretroviral therapy and virological suppression goals: a population-based survey publication-title: Lancet HIV doi: 10.1016/S2352-3018(16)00037-0 – volume: 2011 start-page: 567408 year: 2011 ident: 10.1016/S2468-2667(17)30066-X_bib23 article-title: Association of low-risk human papillomavirus infection with male circumcision in young men: results from a longitudinal study conducted in Orange Farm (South Africa) publication-title: Infect Dis Obstet Gyneco doi: 10.1155/2011/567408 – year: 2016 ident: 10.1016/S2468-2667(17)30066-X_bib13 – volume: 9 start-page: 30314 year: 2016 ident: 10.1016/S2468-2667(17)30066-X_bib27 article-title: Prospects for HIV control in South Africa: a model-based analysis publication-title: Glob Health Action doi: 10.3402/gha.v9.30314 – volume: 30 start-page: 2107 year: 2016 ident: 10.1016/S2468-2667(17)30066-X_bib15 article-title: Level of viral suppression and the cascade of HIV care in a South African semi-urban setting in 2012 publication-title: AIDS doi: 10.1097/QAD.0000000000001155 – volume: 12 start-page: 196 year: 2015 ident: 10.1016/S2468-2667(17)30066-X_bib4 article-title: Epidemiological trends for HIV in southern Africa: implications for reaching the elimination targets publication-title: Curr HIV/AIDS Rep doi: 10.1007/s11904-015-0264-x – year: 2013 ident: 10.1016/S2468-2667(17)30066-X_bib19 – volume: 14 start-page: 627 year: 2014 ident: 10.1016/S2468-2667(17)30066-X_bib10 article-title: Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(13)70363-3 – volume: 82 start-page: 101 year: 2006 ident: 10.1016/S2468-2667(17)30066-X_bib22 article-title: Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis publication-title: Sex Transm Infec doi: 10.1136/sti.2005.017442 – volume: 33 start-page: 939 year: 2015 ident: 10.1016/S2468-2667(17)30066-X_bib14 article-title: Costs to health services and the patient of treating tuberculosis: a systematic literature review publication-title: Pharmacoeconomics doi: 10.1007/s40273-015-0279-6 – volume: 20 start-page: 66 year: 2007 ident: 10.1016/S2468-2667(17)30066-X_bib21 article-title: Male circumcision as a preventive measure against HIV and other sexually transmitted diseases publication-title: Curr Opin Infect Dis doi: 10.1097/QCO.0b013e328011ab73 – volume: 10 start-page: e0142908 year: 2016 ident: 10.1016/S2468-2667(17)30066-X_bib26 article-title: Impact and cost of the HIV/AIDS national strategic plan for Mozambique, 2015–2019—projections with the Spectrum/Goals model publication-title: PLoS One doi: 10.1371/journal.pone.0142908 – volume: 87 start-page: 186 year: 2009 ident: 10.1016/S2468-2667(17)30066-X_bib12 article-title: New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya publication-title: Bull World Health Organ doi: 10.2471/BLT.08.051474 – volume: 355 start-page: 1131 year: 2000 ident: 10.1016/S2468-2667(17)30066-X_bib11 article-title: Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active anti-retroviral therapy: a collaborative re-analysis publication-title: Lancet doi: 10.1016/S0140-6736(00)02061-4 – volume: 107 start-page: 19485 year: 2010 ident: 10.1016/S2468-2667(17)30066-X_bib18 article-title: Antiretroviral therapy for tuberculosis control in nine African countries publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1005660107 – volume: 165 start-page: 325 year: 2016 ident: 10.1016/S2468-2667(17)30066-X_bib3 article-title: The anticipated clinical and economic effects of 90–90–90 in South Africa publication-title: Ann Intern Med doi: 10.7326/M16-0799 – ident: 10.1016/S2468-2667(17)30066-X_bib28 – year: 2016 ident: 10.1016/S2468-2667(17)30066-X_bib1 – volume: 7 start-page: e1000178 year: 2010 ident: 10.1016/S2468-2667(17)30066-X_bib9 article-title: Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey publication-title: PLoS Med doi: 10.1371/journal.pmed.1000178 – volume: 10 start-page: e1001509 year: 2013 ident: 10.1016/S2468-2667(17)30066-X_bib20 article-title: Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys publication-title: PLoS Med doi: 10.1371/journal.pmed.1001509 – volume: 199 start-page: 14 year: 2009 ident: 10.1016/S2468-2667(17)30066-X_bib25 article-title: Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in orange farm, South Africa publication-title: J Infect Dis doi: 10.1086/595566 – year: 2015 ident: 10.1016/S2468-2667(17)30066-X_bib5 – volume: 23 start-page: 2039 year: 2009 ident: 10.1016/S2468-2667(17)30066-X_bib7 article-title: AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic publication-title: AIDS doi: 10.1097/QAD.0b013e32833016ce – volume: 44 start-page: 874 year: 2007 ident: 10.1016/S2468-2667(17)30066-X_bib6 article-title: HIV infection presenting in older children and adolescents: a case series from Harare, Zimbabwe publication-title: Clin Infect Dis doi: 10.1086/511878 – volume: 88 start-page: 428 year: 2010 ident: 10.1016/S2468-2667(17)30066-X_bib8 article-title: Survey of children accessing HIV services in a high prevalence setting: time for adolescents to count? publication-title: Bull World Health Organ doi: 10.2471/BLT.09.066126 – ident: 10.1016/S2468-2667(17)30066-X_bib17 – volume: 53 start-page: 111 year: 2010 ident: 10.1016/S2468-2667(17)30066-X_bib24 article-title: Association of oncogenic and nononcogenic human papillomavirus with HIV incidence publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181b327e7 – reference: 29253481 - Lancet Public Health. 2017 May;2(5):e205-e206 |
| SSID | ssj0001826652 |
| Score | 2.1275687 |
| Snippet | In September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone infected with HIV irrespective of their CD4 cell count.... SummaryBackgroundIn September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone infected with HIV irrespective of their... Background: In September, 2016, South Africa adopted a policy of providing antiretroviral treatment to everyone infected with HIV irrespective of their CD4... |
| SourceID | doaj proquest pubmed crossref elsevier |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e223 |
| SubjectTerms | Adult Anti-Retroviral Agents - therapeutic use Health Policy HIV Infections - epidemiology HIV Infections - prevention & control Humans Internal Medicine Models, Theoretical Program Evaluation Public Health South Africa - epidemiology Treatment Outcome Tuberculosis - epidemiology Tuberculosis - prevention & control |
| Title | Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S246826671730066X https://www.clinicalkey.es/playcontent/1-s2.0-S246826671730066X https://dx.doi.org/10.1016/S2468-2667(17)30066-X https://www.ncbi.nlm.nih.gov/pubmed/29253488 https://www.proquest.com/docview/1978715025 https://doaj.org/article/ca9aa804f2094784b4625ebf8f1637b0 |
| Volume | 2 |
| WOSCitedRecordID | wos000425586300010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 2468-2667 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001826652 issn: 2468-2667 databaseCode: DOA dateStart: 20160101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2468-2667 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001826652 issn: 2468-2667 databaseCode: M~E dateStart: 20160101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA66eBBEfDurLhE86KHdniTdlXhT2WU9uCz4oG8hTxh26ZHpGY_7260kPe0uKOPBy8A0qU5TVVP1paeqPkJe8ToyzEKikgpiJbiJlUEkXkVQTe0Vb4IvZBNweiq7Tp1dofpKNWFlPHBR3KEzyhhZi8jwIAJSWIGIPdgoIyIJsPm0jqjnymEqv11B1Nxmuh2WWovwC_xu3zn8Ml18PYc3PKXdqruWmPL8_mv56W_4M-eh43vk7ggg6fvy4PfJjdA_IHfK2zdamooekvOzVHaFQYya3lO8Z26oHCgiVIqIj44F6nQZ6cmn73nRemPDym0ulsNioIueZm49WmiE3lFDfaGux60zeU7qYqd5Nu0j8u346OvHk2qkVahcI2FduSiiU7YFDG3GOI-HGPCmASfqCMJ6UxuQRoqAKmYy-AigDHdcWuEYruWPyV6_7MNTQj0HU4NtEQYgrvIc4XobeaOMUNa1oGZEbHWq3ThzPFFfXOipuCyZQidT6DnobArdzcjbSexHGbqxS-BDMti0OM3MzhfQk_ToSXqXJ81IuzW33ralYiDFGy127Q5_EgzDGA4GPdcD03WRTsJzyKIoKSfJEfEUJPMvm77ceqTGiJD-5jF9WG5wM4VBGHE-a2bkSXHVSTFMsYZjzN7_Hwp7Rm6zBHJy-edzsrdebcILcsv9XC-G1QG5CZ08yD9L_Px8efQLOjQzVw |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Progress+and+prospects+for+the+control+of+HIV+and+tuberculosis+in+South+Africa%3A+a+dynamical+modelling+study&rft.jtitle=The+Lancet.+Public+health&rft.au=Dr+Brian+G+Williams%2C+PhD&rft.au=Somya+Gupta%2C+MA&rft.au=Matthew+Wollmers%2C+MA&rft.au=Reuben+Granich%2C+MD&rft.date=2017-05-01&rft.pub=Elsevier&rft.issn=2468-2667&rft.eissn=2468-2667&rft.volume=2&rft.issue=5&rft.spage=e223&rft.epage=e230&rft_id=info:doi/10.1016%2FS2468-2667%2817%2930066-X&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_ca9aa804f2094784b4625ebf8f1637b0 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F24682667%2FS2468266717X00054%2Fcov150h.gif |